1) DeVane CL, Liston HL, Markowitz JS:Clinical pharmacokinetics of sertraline. Clin Pharmacokinet 41:1247-1266, 2002
2) Durif F, Vidailhet M, Bonnet AM, et al:Levodopa-induced dyskinesias are improved by fluoxetine. Neurology 45:1855-1858, 1995
3) Jeste DV, Rockwell E, Harris MJ, et al:Conventional vs. newer antipsychotics in elderly patients. Am J Geriatr Psychiatry 7:70-76, 1999
4) Kane JM, Woerner M, Lieberman JA:Tardive dyskinesia:Prevalence, incidence, and risk factors. Psychopharmacology 2:72-78, 1988
5) Khouzam HR, Emes R, Gill T, et al:The antidepressant sertraline:A review of its uses in a range of psychiatric and medical conditions. Compr Ther 29:47-53, 2003
6) Koran LM, Gelenberg AJ, Kornstein SG, et al:Sertraline versus imipramine to prevent relapse in chronic depression. J Affect Disord 65:27-36, 2001
7) Mander A, McCausland M, Workman B, et al:Fluoxetine induced dyskinesia. Aust N Z J Psychiatry 28:328-330, 1994
8) Miller R, Chouinard G:Loss of striatal cholinergic neurons as a basis for tardive and L-dopa-induced dyskinesias, neuroleptic-induced supersensitivity psychosis and refractory schizophrenia. Biol Psychiatry 34:713-738, 1993
9) Neale R, Fallon S, Gerhardt S, et al:Acute dyskinesias in monkeys elicited by halopemid, mezilamine and the "antidyskinetic" drugs, oxiperomide and tiapride. Psychopharmacology 75:254-257, 1981
10) Ossowska K:Neuronal basis of neuroleptic-induced extrapyramidal side effects. Pol J Pharmacol 54:299-312, 2002
11) Porsolt RD, Jalfre M:Neuroleptic-induced acute dyskinesias in rhesus monkeys. Psychopharmacology 75:16-21, 1981
12) Preskorn SH:Outpatient management of depression. In:Caddo OK, ed. A Guideline for the Practitioner Professional Communication Inc 2nd ed. Professional Communications. Caddo, Oklahoma, p85, 1999
13) Wistedt AA, Agren H, Ekselius L, et al:Sertraline versus paroxetine in major depression:Clinical outcome after six months of continuous therapy. J Clin Psychopharmacol 20:645-652, 2000